The administration of LPSF/GQ-02 inhibited the hepatic injury, decreased inflammatory markers and increased sensitivity to insulin, suggesting an important role in the improvement of NAFLD. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.